Randomized trial evaluates cytokine release and biodistribution in bispecific antibodies, suggesting CD3 affinity tuning enhances therapy.
Key Points
This research aims to determine how different binding affinities to CD3 affect the efficacy and toxicity of bispecific antibodies designed for cancer therapy.
Engineered bispecific antibodies with varying CD3 affinities were tested.
Tumor cell killing ability was evaluated in vitro.
Biodistribution and pharmacokinetics were assessed in vivo.